Objectives. Secondary amyloidosis is the most important complication of FMF and endothelial function is more severely impaired. Elevated asymmetric dimethyl arginine (ADMA) may mediate the excess cardiovascular disease (CVD) risk of this group. We aimed to compare endothelial function characteristics, including ADMA, in patients with FMF-related amyloidosis and primary glomerulopathies and to define risk factors for a CVD event.
Introduction
FMF is an autosomal recessive disorder common in eastern Mediterranean countries such as Turkey and is associated with the development of secondary amyloidosis [1] . Secondary amyloidosis in turn becomes a prevalent cause of proteinuria and chronic kidney disease (CKD) in this geographical region [2] , with a prognosis worse than other CKD aetiologies [35] .
We have previously showed that endothelial function is more severely impaired in patients with amyloidosis than in individuals with other glomerulopathies [3] . At the same time, asymmetric dimethyl arginine (ADMA), considered to be a causative factor in endothelial dysfunction (ED) [4, 5] , is also increased in amyloidosis patients [3, 6] .
In this study we aimed (i) to discern the clinical, biochemical and endothelial function characteristics of nephrotic syndrome patients with FMF-related amyloidosis as their primary aetiology and (ii) to evaluate the possible association between ADMA levels and impaired FMD response with the cardiovascular disease (CVD) risk in these individuals. We studied these issues in, to the best of our knowledge, the largest collection of nephrotic syndrome patients with amyloidosis reported so far.
Patients and methods

Patients
In this case cohort study, patients were recruited from the renal outpatient clinic at Gü lhane School of Medicine, Ankara, Turkey, between September 2003 and December 2011. Patients who had glomerulopathy were followed by a comprehensive patient-based registry that was established at Gü lhane School of Medicine in 2003 and is described elsewhere in more detail [3] . Among a referred population of 874 patients without established renal disease, 459 had isolated proteinuria [24 h protein excretion >3500 mg/day with normal glomerular filtration rate (GFR)] (Fig. 1 , all recruited patients were assigned to two possible groups: FMF-related amyloidosis (n = 98) and those with other primary glomerulopathies (PGs; n = 102), respectively. The ethics committee of the Gü lhane School of Medicine approved the study and informed consent was obtained from each subject.
Procedures
All enrolled subjects were evaluated by standard physical examination and routine biochemical laboratory tests, including liver and kidney function tests and 24-h urinary protein measurements. Venous blood samples were taken and flow-mediated dilatation (FMD) assessment was performed following a 2-week washout period, during which time no vasoactive drugs (including colchicine) were given.
Laboratory and imaging procedures
Arterial blood pressure (BP) was measured three times in the morning after a 15-min resting period and the mean values were calculated. Blood sampling was done after an overnight fast. Fasting plasma glucose (FPG), total protein, serum albumin, total cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were determined by enzymic colorimetry on an Olympus AU 600 autoanalyser using reagents from Olympus Diagnostics (Hamburg, Germany). Low-density lipoprotein (LDL) cholesterol was calculated by Friedewald's formula [9] . Twenty-four-hour proteinuria was determined by a turbidimetric test using trichloroacetic acid. The serum basal insulin value was determined using a coated tube method (DPC, Los Angeles, CA, USA). Renal function was estimated by the modified modification of diet in renal disease formula (in ml/min) and expressed per High-sensitivity CRP levels in serum (hsCRP) were determined by the turbidimetric fixed rate method by an automated analyser (AU-2700; Olympus, Mishima, Japan). The levels of pentraxin 3 (PTX3) were measured from frozen serum using a commercial ELISA kit (Quantakine DPTX 30; R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Measurements of ADMA and SDMA Measurements of serum ADMA and symmetric dimethyl arginine (SDMA) were done using HPLC, as described by Chen et al. [12] . In brief, to 1 ml of serum, 20 mg of 5-sulphosalicylic acid was added and the mixture was left in an ice bath for 10 min. The precipitated protein was removed by centrifugation at 2000 g for 10 min. Ten microlitres of the supernatant filtered through a 0.2 mm filter was mixed with 100 ml of derivatization reagent (prepared by dissolving 10 mg o-phthaldialdehyde in 0.5 ml of methanol, 2 ml of 0.4 M borate buffer (pH 10.0) and 30 ml of 2-mercaptoethanol) and then injected into the chromatographic system. Separation of ADMA was achieved with a 150 Â 4 mm inside diameter (I.D.) Nova-pak C18 column with a particle size of 5 mm (Millipore, Milford, MA, USA) using 50 mM sodium acetate (pH 6.8), methanol and tetrahydrofurane as the mobile phase (A, 82:17:1; B, 22:77:1) at a flow rate of 1.0 ml/min. The areas of peaks detected by the fluorescent detector (Ex: 338 nm; Em: 425 nm) were used as quantification. The variability of the method was <7% and the detection limit of the assay was 0.01 mM.
Ultrasonic measurements
We determined ED according to Celermajer et al. [13] . Measurements were made by a single observer using an ATL 5000 US system (Advanced Technology Laboratories, Bothell, WA, USA) with a 12 MHz probe. The subjects remained at rest in the supine position for at least 15 min before the examination started. The subject's arm was comfortably immobilized in the extended position to allow consistent recording of the brachial artery 24 cm above the antecubital fossa. Three adjacent measurements of end-diastolic brachial artery diameter were made from single two-dimensional (2D) frames. All US images were recorded on videotape for subsequent blinded analysis. A pneumatic tourniquet was then inflated to 200 mmHg with obliteration of the radial pulse. After 5 min the cuff was deflated. Flow measurements were made 60 sec after deflation. The maximum FMD (FMD max ) diameters were calculated as the average of three consecutive maximum diameter measurements. The percentage change in average FMD max diameter compared with baseline resting diameter was defined as the flow-mediated diameter change. The intraobserver coefficient of variation for FMD was 5.1%.
Statistical analysis
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) for Windows, version 15.0 (SPSS, Chicago, IL, USA). Descriptive statistics were represented as frequency and percentage for categorical variables and as median (minimummaximum) for continuous variables, as appropriate. Distributions of variables were evaluated by a one-sample KolmogorovSmirnov test. Independent samples t test or MannWhitney U test was used to compare continuous variables between groups. Categorical variables were compared by chi-square test.
Multivariate logistic regression analysis was performed to estimate the factors associated with FMF amyloidosis. Variables that had P-values 40.20 in the univariate analysis were included in the multivariate analysis. The backward elimination method was used to select entry predictor variables. The success of the final model was evaluated by using À2 log likelihood ratio values.
Univariate survival analysis was performed to compare the CVD-free period by the KaplanMeier method and the differences between survival curves were evaluated using the log-rank test. The variables that had a statistically significant effect on the hazard ratio were included in the Cox proportional hazard method as a multivariate analysis. The model was then reduced by using the backward elimination method and the best-fitting models were reported.
Results
There were 102 patients [62 male (60.8%), median age 34 years (range 1956)] with proteinuria due to PG and a further 98 patients [61 male (62.2%), median age 32 years (range 1841)] with amyloidosis due to FMF. Reported symptoms of the patients with FMF-related amyloidosis who were being treated with colchicine were fever (36.7%), abdominal pain (33.7%), myalgia (30.6%), arthritis (28.6%), pleuritis (17.3%), erysipelas (14.3%) and peritonitis (10.2%). A family history of FMF or amyloidosis was present in 28.6% and 21.4% of the patients, respectively. As a complication of FMF, appendectomy was performed in nearly a quarter of patients (24.5%). Starting with the most frequently reported, the primary aetiology of proteinuria according to renal biopsy in the non-amyloidosis patients was minimal change in disease (23.5%), focal segmental glomerulosclerosis (19.6%), membranous nephropathy (15.7%), membranoproliferative glomerulonephritis (12.7%), IgA nephropathy (8.8%), secondary focal segmental glomerulosclerosis (7.8%), mesangial proliferation (5.9%) and LN (5.9%).
Clinical and laboratory characteristics
Comparison of clinical and laboratory features between the two study groups is presented in Table 1 . There was a statistically significant difference in terms of age (P = 0.005): median age at diagnosis in patients with FMF-related amyloidosis was 16 years (range 625) and 71.4% of patients were 418 years at the time of diagnosis of amyloidosis. BMI as well as systolic and diastolic BP were similar between the groups. The groups differed, however, in their serum albumin levels and most of the metabolic markers of blood lipids. In addition, patients with amyloidosis showed higher levels of insulin (P < 0.01), HOMA (P < 0.01) and FPG (P = 0.02).
Furthermore, whereas levels of ADMA and SDMA were significantly higher (P < 0.001), the FMD percentage (P < 0.001) was significantly lower in the FMF-related amyloidosis group (Table 1) . Inflammatory markers such as hsCRP and PTX3 were also higher in this group. Multivariate factors associated with the presence of amyloidosis are shown in Table 2 . After stepwise exclusion, triglyceridaemia and higher ADMA levels were found along with the presence of amyloidosis, while albuminaemia was a negative predictor.
Follow-up for CVD events CVD-free survival time was calculated from the first admission to our centre, with no loss of follow-up. The median follow-up time for patients with FMF-related amyloidosis was 40 months (range 647), while follow-up for patients with other PGs was 39 months (range 844). For the purpose of this study, a combined endpoint of fatal and non-fatal cardiovascular events was created. In the FMF-related amyloidosis group, cardiovascular events were registered in 25 patients: 7 patients had one or more myocardial infarctions, 9 had angina pectoris, 2 had percutaneous transluminal coronary angiography and 4 had left ventricular dysfunction. Two patients suffered cerebrovascular disease and 1 had signs of peripheral atherothrombotic vascular disease. In addition, 11 deaths due to CVD were registered as a result of coronary heart disease (n = 6), sudden death (n = 3) and stroke (n = 2).
In patients with other PGs, cardiovascular events were registered in 13 individuals: 3 had one or more myocardial infarctions, 4 had angina pectoris, 1 had percutaneous transluminal coronary angiography and 2 had left ventricular dysfunction. Two patients suffered cerebrovascular disease and one had signs of peripheral atherothrombotic vascular disease. In addition, five deaths due to CVD were registered as a result of coronary heart disease (n = 3), sudden death (n = 1) and stroke (n = 1).
KaplanMeier curves
According to the KaplanMeier survival analyses, patients with FMF-related amyloidosis were more likely to suffer a cardiovascular event (combining fatal and non-fatal CV events) (Fig. 2) . The 3-year survival probability was 79% for the PG group and 60% for the amyloidosis group.
Given the relative rarity of amyloidosis patients, Table 3 compares the patient characteristics of these individuals depending on whether they suffer a cardiovascular event during follow-up. Both ADMA and SDMA were higher Risk factors associated with the probability of suffering a cardiovascular event during follow-up were evaluated by Cox regression analysis and are presented in Table 4 . When studying all patients together, age, inflammation, FMD and ADMA levels were factors independently contributing to the risk of cardiovascular events. When studying risk factors in each aetiology group separately, ADMA and FMD levels arose as the strongest predictors of cardiovascular risk.
Discussion
The results of the present study show that FMF patients who develop nephrotic syndrome due to amyloidosis carry a higher risk for cardiovascular morbidity when compared with other nephrotics. In our survey, patients in the group of FMF-related amyloidosis have a higher risk of CV events than those with other PGs. The same group also has increased ADMA synthesis and inflammatory markers, as well as worse endothelial function, all of which may mediate this excess cardiovascular risk. It is tempting to speculate that the increased inflammation is making the endothelium vulnerable to injury in these patients.
Systemic AA amyloidosis is a long-recognized, severe complication of several chronic inflammatory diseases. All the amyloidosis patients involved in this study had FMF, a recessive disorder relatively more common in Mediterranean countries such as ours. Renal involvement usually follows in FMF-related amyloidosis, which is thus a [17] reported increased cardiovascular mortality in the course of renal transplantation in patients with amyloidosis when compared with patients having non-amyloid renal disease [5] . Two other case series have described the increased cardiovascular risk of dialysis patients with amyloidosis secondary to RA [18, 19] . Thus far, no prospective study had been performed to compare the cardiovascular mortality and morbidity of early CKD patients with FMFrelated amyloidosis, perhaps given the difficulty of gathering a sufficient sample size in this relatively rare condition. Thus, and to the best of our knowledge, ours represents the largest study of FMF-related amyloidosis patients of this kind. We show that this aetiology associates with an increased cardiovascular risk as compared with other CKD aetiologies within the same proteinuric range.
Proteinuria is indeed a hallmark of renal disease, but also a significant cardiovascular risk factor [20] . Increased inflammatory activity, insulin resistance and dyslipidaemia are thought to be significant contributors to the cardiovascular damage associated with proteinuria [1416] . However, ED is the main mechanism involved in the time course of vascular disease [4, 5] . Expanding previous reports [3, 6, 21], we show in our study that patients with nephrotic syndrome due to FMF-related amyloidosis suffer from ED and present with increased levels of ADMA and inflammatory biomarkers as compared with other aetiologies. In the general population, ADMA levels are independently associated with ED [22] and have been reported to be elevated in patients with CVD [23] . Because the kidneys provide a significant route for clearance of methylarginines, it is perhaps not surprising that, as in more severe CKD stages [24, 25] , ADMA concentrations are increased in patients even at this early stage in our study. Inflammation, defined here as elevated serum CRP and PTX3, is also known to influence ADMA and has been proposed to be one factor linking ADMA to CVD [26] .
Because ADMA in this study was independently associated with the presence of amyloidosis, and together with FMD derangements was a predictor of cardiovascular outcomes, we hypothesize that ED resulting from increased ADMA concentrations may be one factor contributing to the elevated risk of CVD in this patient group.
There are several limitations to this study. The observational design may preclude any conclusion about causality, and the strict inclusion criteria, albeit important for the research question addressed, produce a patient group exempted from co-morbidities and certain medications that may not be representative of all nephrotic syndrome patients. Moreover, we do not have genotype results for the entire group of patients in FMF-related amyloidosis. Also, although we measured circulating methylarginines, it is not known whether these are biologically active in themselves or just a reflection of high intracellular levels. Finally, we did not evaluate the environmental confounders that may also have influenced the clinical and laboratory findings.
To conclude, our data suggest that FMF-related amyloidosis as a cause of nephrotic syndrome heralds a poor prognosis and is accompanied by ED, higher ADMA levels and inflammation. However, it is hoped that effective control of inflammation and disease in these patients will save them from these devastating complications.
Rheumatology key messages
. Patients with FMF-related amyloidosis have increased cardiovascular disease event risk. . Prognosis is poor in patients with nephrotic-range proteinuria due to FMF-related amyloidosis. . High asymmetric dimethyl arginine levels may be related to poor prognosis in patients with amyloidosis. 
